HST Global, Inc. Files Annual Report on Form 10-K for Fiscal Year Ended December 31, 2023

TL;DR

<b>HST Global, Inc. has filed its 2023 annual 10-K report, detailing its corporate structure and industry classification.</b>

AI Summary

HST Global, Inc. (HSTC) filed a Annual Report (10-K) with the SEC on April 5, 2024. HST Global, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Nevada and its principal executive offices are located at 150 Research Drive, Hampton, VA 23666. HST Global, Inc. is classified under the Pharmaceutical Preparations industry (SIC code 2834). The company was formerly known as NT Holding Corp., ABSS Corp., and UNICO INC. The filing indicates that HST Global, Inc. is not a well-known seasoned issuer and has not filed all required reports in the preceding 12 months.

Why It Matters

For investors and stakeholders tracking HST Global, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of HST Global, Inc.'s financial performance and operational status for the fiscal year 2023, which is crucial for investors to assess the company's health and future prospects. The information within this report, including its industry classification and former company names, helps contextualize its business operations and historical evolution for stakeholders.

Risk Assessment

Risk Level: medium — HST Global, Inc. shows moderate risk based on this filing. The filing explicitly states the company is not a well-known seasoned issuer and has not filed all required reports in the preceding 12 months, indicating potential compliance or reporting issues.

Analyst Insight

Investors should review the full 10-K filing to understand the specific reasons for the company's reporting status and assess any associated risks.

Key Numbers

• 2023-12-31 — Fiscal Year End (The report covers the fiscal year ending on this date.)
• 000-15303 — Commission File Number (SEC file number for HST Global, Inc.)
• 73-1215433 — IRS Employer Identification No. (Tax identification number for the company.)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations.)
• 2004-10-19 — Date of Name Change (Date when the company changed its name from NT HOLDING CORP.)
• 2002-05-22 — Date of Name Change (Date when the company changed its name from ABSS CORP.)
• 1995-07-26 — Date of Name Change (Date when the company changed its name from UNICO INC.)

Key Players & Entities

• HST Global, Inc. (company) — Filer and registrant name
• NT HOLDING CORP. (company) — Former company name
• ABSS CORP (company) — Former company name
• UNICO INC (company) — Former company name
• 2023-12-31 (date) — Fiscal year end date
• 150 Research Drive, Hampton, VA 23666 (address) — Principal executive offices address
• 757-766-6100 (phone) — Business phone number
• 2834 (industry_code) — Standard Industrial Classification code for Pharmaceutical Preparations

FAQ

Risk Factors

• Reporting Compliance [high — regulatory]: The company is not a well-known seasoned issuer and has not filed all required reports in the preceding 12 months, indicating potential regulatory or compliance challenges.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.

Key Financial Figures

• $0.001 — ommon stock has been reported as low as $0.001 per share. As such, the Company's commo
• $5.00 — urity that has a market price less than $5.00 per share, subject to certain exception
• $146,210 — Company incurred operating expenses of $146,210 for the year ended December 31, 2023, c
• $145,074 — ar ended December 31, 2023, compared to $145,074 in 2022. The increase in expenses in 20
• $1,526 — ash balance as of December 31, 2023 was $1,526. Page 6 Cash Flows Year Ended Yea

Filing Documents

• hstc-20231231.htm (10-K) — 253KB
• exhibit31-1.htm (EX-31) — 8KB
• exhibit31-2.htm (EX-31) — 8KB
• exhibit32-1.htm (EX-32) — 4KB
• exhibit32-2.htm (EX-32) — 4KB
• 0001674796-24-000003.txt (&nbsp;) — 1485KB
• hstc-20231231_cal.xml (EX-101.CAL) — 14KB
• hstc-20231231_def.xml (EX-101.DEF) — 22KB
• hstc-20231231_lab.xml (EX-101.LAB) — 92KB
• hstc-20231231_pre.xml (EX-101.PRE) — 79KB
• hstc-20231231.xsd (EX-101.SCH) — 19KB
• hstc-20231231_htm.xml (XML) — 95KB

Forward Looking Statements 4

Forward Looking Statements 4

Risk Factors 4

Item 1A. Risk Factors 4

Unresolved Staff Comments 4

Item 1B. Unresolved Staff Comments 4

Properties 4

Item 2. Properties 4

Legal Proceedings 4

Item 3. Legal Proceedings 4

Mine Safety Disclosures 4

Item 4. Mine Safety Disclosures 4 Part II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 5

Selected Financial Data 5

Item 6. Selected Financial Data 5

Management's Discussion and Analysis of Financial Condition and Results of Operations 6

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 6

Quantitative and Qualitative Disclosures About Market Risk 7

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 7

Financial Statements and Supplementary Data 7

Item 8. Financial Statements and Supplementary Data 7

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 18

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 18

Controls and Procedures 18

Item 9A. Controls and Procedures 18

Other Information 19

Item 9B. Other Information 19 Part III

Directors, Executive Officers, and Corporate Governance 20

Item 10. Directors, Executive Officers, and Corporate Governance 20

Executive Compensation 21

Item 11. Executive Compensation 21

Security Ownership of Certain Beneficial Owners and Management and Related

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 25

Certain Relationships and Related Transactions, and Director Independence 25

Item 13. Certain Relationships and Related Transactions, and Director Independence 25

Principal Accountant Fees and Services 26

Item 14. Principal Accountant Fees and Services 26 Part IV

Exhibits and Financial Statement Schedules 26

Item 15. Exhibits and Financial Statement Schedules 26 Signatures 27 Page 3 PART I

BUSINESS

ITEM 1. BUSINESS A. BUSINESS DEVELOPMENT There have been no changes to our business development since our last annual report on Form 10-K. We are still in the start-up stage and have not commenced operations. B. FINANCIAL INFORMATION ABOUT SEGMENTS As defined by generally accepted accounting principles ("GAAP"), we do not have any segments separate and apart from our business as a whole. Accordingly, there are no measures of revenue from external customers, profit and loss, or total assets aside from what is reported in the Financial Statements attached to this Form 10-K. C. BUSINESS OF THE COMPANY HST Global, Inc. (the "Company") was founded as an integrated health and wellness biotechnology company with a plan to develop and /or acquire a network of wellness centers worldwide that would be primarily focused on the homeopathic and alternative treatment of late stage cancer. To date we have been unable to initiate our original business plan. While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams.

RISK FACTORS

ITEM 1A. RISK FACTORS Not required by smaller reporting companies.

UNRESOLVED STAFF COMMENTS

ITEM 1B. UNRESOLVED STAFF COMMENTS None.

PROPERTIES

ITEM 2. PROPERTIES The Company's executive offices are located at 150 Research Dr., Hampton VA. We currently share these offices with The Health Network, Inc. ("THN"), of which Ron Howell (our Chief Executive Officer and Chairman) is President. We have no formal sublease or rental agreement with THN; however, we are currently occupying the space at no cost. The combined office and warehouse space is 42,600 square feet, of which we use a small portion.

LEGAL PROCEEDINGS

ITEM 3. LEGAL PROCEEDINGS None.

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES Not applicable to the Company. Page 4 PART II

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market Informatio n Our common stock is quoted in United States markets on the Over-The-Counter Bulletin Boards ("OTC BB"), under the symbol "HSTC.OB." There is no assurance that the common stock will continue to be traded on the OTC BB or that any liquidity exists for our shareholders. Penny Stock Regulations Our common stock is quoted in United States markets on the OTC BB under the symbol "HSTC.OB." The sale price of our common stock has been reported as low as $0.001 per share. As such, the Company's common stock may be subject to provisions of Section 15(g) and Rule 15g-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), commonly referred to as the "penny stock rule." Section 15(g) sets forth certain requirements for transactions in penny stocks, and Rule 15g-9(d) incorporates the definition of "penny stock" that is found in Rule 3a51-1 of the Exchange Act. The Securities and Exchange Commission ("SEC") generally defines "penny stock" to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. As long as the Company's common stock is deemed to be a penny stock, trading in the shares will be subject to additional sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. Dividends The Company has not issued any dividends on its common stock to date, and does not intend to issue any dividends on the common stock in the near future. We currently intend to use all profits to further the growth and development of the Company. Number of Shares Outstanding As of December 31, 2023, the Company had 200,000,000 shares of common stock authorized with 5,248,582 issued and outstanding. These shares were held by approximately 602 shareholders of record. The Company has 10,000,000 shares of preferred

SELECTED FINANCIAL DATA

ITEM 6. SELECTED FINANCIAL DATA Not required by smaller reporting companies. Page 5

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Forward-Looking Statements

Forward-Looking Statements Overview The Company was founded as an integrated health and wellness biotechnology company with a plan to develop and /or acquire a network of wellness centers worldwide that would be primarily focused on the homeopathic and alternative treatment of late stage cancer. To date we have been unable to initiate our original business plan. While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams. Plan of Operation General and administrative expenses consist primarily of salaries and related personnel costs, professional fees, business insurance, rent, general legal activities, and other corporate expenses. We have never been profitable and do not anticipate having net income unless and until we develop and/or acquire our wellness centers and/or develop new channels of distribution. With respect to our current activities, this is not likely to occur until we obtain significant additional funding. We cannot provide any assurance that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain, or complete additional corporate partne

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK None.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Description Page Reports of Independent Registered Public Accounting Firms ( PCAOB Firm ID 76 ) 8 Consolidated Balance Sheets 9 Consolidated Statements of Operations 10 Consolidated Statements of Stockholders' Deficit 11 Consolidated Statements of Cash Flows 12

Notes to Consolidated Financial Statements 13

Notes to Consolidated Financial Statements 13 Page 7 Report of Independent Registered Public Accounting Firm Board of Directors and Stockholders HST Global, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of HST Global, Inc. (the "Company") as of December 31, 2023 and 2022, and the related consolidated statements of statements of operations, stockholders' deficit, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of HST Global, Inc. as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has yet to establish an ongoing source of revenues sufficient to cover its operating costs which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulati

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Years Ended December 31, 2023 and 2022 NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES HST Global, Inc. ("the Company") was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc ("Health Source"). At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia. The Company is an integrated health and wellness biotechnology company with a plan to develop and/or acquire a network of wellness centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases. In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases. To date we have been unable to initiate our original business plan. While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements and related no

View Full Filing

View this 10-K filing on SEC EDGAR